ClinicalTrials.Veeva

Menu

Novel Index (PIMR) in PAH

University of California, Los Angeles (UCLA) logo

University of California, Los Angeles (UCLA)

Status

Completed

Conditions

Pulmonary Hypertension

Treatments

Other: Pulmonary Index of Microcirculatory Resistance
Other: Right Ventricle Index of Microcirculatory Resistance

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05812976
IRB#22-001088

Details and patient eligibility

About

The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. This study is intended to translate prior work in heart arteries to the PAH space and invasively measure the resistance of the small arteries of the lung (pulmonary index of microcirculatory resistance [PIMR]) and the coronary artery supplying the right ventricle (acute marginal of the RCA; RV-IMR). Importantly, these measurements will be made during standard of care cardiac catheterizations (right heart catheterization [RHC] +/- left heart catheterization). The correlation between these new indices and the standard ones measured during RHC typically used to determine the severity of pulmonary hypertension will be analyzed. In addition, among newly diagnosed patients, the study will evaluate how these indices change 6 months after starting treatment. Finally, the association of these indices with clinical outcomes at 1 year will be assessed. The findings from this study may deliver an immediate impact to patient care by identifying a new metric to help better identify those who may benefit from a more intensive, personalized treatment regimen.

Enrollment

22 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of Group 1 PAH with invasive pulmonary hypertension defined as: Mean pulmonary arterial pressure ≥ 20 mmHg, pulmonary capillary wedge pressure < 15 mmHg, and pulmonary vascular resistance ≥ 3 Wood units.
  • Serum creatinine < 2.0 mg/dL
  • Able to provide informed written consent

Exclusion criteria

  • Other groups/forms of pulmonary hypertension (i.e. groups 2-5)
  • Contraindicated to undergo fluoroscopy and/or coronary angiography
  • Pregnancy

Trial design

22 participants in 1 patient group

PAH Patients
Description:
Pulmonary Index of Microcirculatory Resistance (PIMR) and Right Ventricle Index of Microcirculatory Resistance (RV-IMR) measurements during standard-of-care right +/- left heart catheterization at baseline and among those who undergo a standard-of-care right heart catheterization at 6 months.
Treatment:
Other: Right Ventricle Index of Microcirculatory Resistance
Other: Pulmonary Index of Microcirculatory Resistance

Trial contacts and locations

1

Loading...

Central trial contact

Rushi Parikh, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems